Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

797 ARTÍCULOS , VIENDO DEL 646 AL 660

Donanemab for Alzheimer's disease: from preclinical research to the clinical application

Dodel R, Frölich L.

Expert Rev Neurother. 2025 Oct;25(10):1151-1163. doi: 10.1080/14737175.2025.2546868. Epub 2025 Aug 25.

Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial

Rajji TK, Baksh SN, Shade DM, Ismail Z, Burhan AM, Okhravi HR, Padala PR, Rosenberg PB, Schneider LS, Porsteinsson AP, Lyketsos CG; S-CitAD Research Group.

Nat Med. 2025 May;31(5):1586-1591. doi: 10.1038/s41591-025-03569-y. Epub 2025 Mar 25.

Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis

Arroyo-Pacheco N, Sarmiento-Blanco S, Vergara-Cadavid G, Castro-Leones M, Contreras-Puentes N.

Ageing Res Rev. 2025 Feb;104:102620. doi: 10.1016/j.arr.2024.102620. Epub 2024 Dec 3.

Implementing early detection of cognitive impairment in primary care to improve care for older adults

Fowler NR, Partrick KA, Taylor J, Hornbecker M, Kelleher K, Boustani M, Cummings JL, MacLeod T, Mielke MM, Brosch JR, Lee J, Shobin E, Galvin JE, Fillit H, Udeh-Momoh C, Willis DR.

J Intern Med. 2025 Jul;298(1):31-45. doi: 10.1111/joim.20098. Epub 2025 May 23.

Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity

Moscoso A, Heeman F, Raghavan S, Costoya-Sánchez A, van Essen M, Mainta I, Camacho V, Rodríguez-Fonseca O, Silva-Rodríguez J, Perissinotti A, Gu Y, Yun J, Peretti D, Ribaldi F, Coomans EM, Brum WS, Grothe MJ, Aguiar P, Bischof GN, Drzezga A, Seo SW, Villeneuve S, Malpetti M, O'Brien JT, Rowe JB, van de Giessen EM, Ossenkoppele R, Jagust WJ, Smith R, Hansson O, Frisoni GB, Garibotto V, Soleimani-Meigooni DN, Carrillo M, Dickerson BC, La Joie R, Rabinovici GD, Apostolova LG, LaMontagne PJ, Pontecorvo MJ, Johnson KA, Sperling RA, Weiner MW, Petersen RC, Jack CR Jr, Vemuri P, Schöll M; PREVENT-AD Research Group, the Harvard Aging Brain Study, the LEADS Consortium, and the Alzheimer’s Disease Neuroimaging Initiative.

JAMA. 2025 Jul 15;334(3):229-242. doi: 10.1001/jama.2025.7817.

Deferiprone in Alzheimer Disease: A Randomized Clinical Trial

Ayton S, Barton D, Brew B, Brodtmann A, Clarnette R, Desmond P, Devos D, Ellis KA, Fazlollahi A, Fradette C, Goh AMY, Kalinowski P, Kyndt C, Lai R, Lim YY, Maruff P, O'Brien TJ, Rowe C, Salvado O, Schofield PW, Spino M, Tricta F, Wagen A, Williams R, Woodward M, Bush AI.

JAMA Neurol. 2025 Jan 1;82(1):11-18. doi: 10.1001/jamaneurol.2024.3733.

High circulating adropin levels predict long-term blood pressure variability in old adults: evidence from the Multidomain Alzheimer Prevention Trial

Aggarwal G, Salas J, Vellas B, Nguyen AD, Butler AA; MAPT/IHU HealthAge Open Science Group.

Am J Physiol Heart Circ Physiol. 2025 Dec 1;329(6):H1684-H1692. doi: 10.1152/ajpheart.00763.2025. Epub 2025 Nov 18.

Validation status of cognitive digital assessments by the FDA BEST framework and context of use in preclinical AD studies: A systematic review

Porta-Mas C, Grau-Rivera O, Gispert JD, Blasco GS, Sánchez-Benavides G.

Alzheimers Dement. 2025 Dec;21(12):e70753. doi: 10.1002/alz.70753.

Antiamyloid Therapy and Cerebral Blood Flow Changes on MRI: A Potential Longitudinal Biomarker of Treatment Response?

Ricaurte-Fajardo A, Ivanidze J, Zhang D, Mahmud M, Yasen W, Ravdin L, Pahlajani S, Leon M, Nordvig AS, Chiang GC.

AJNR Am J Neuroradiol. 2025 Jul 1;46(7):1439-1445. doi: 10.3174/ajnr.A8654.

The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidence

Aisen P, Bateman RJ, Crowther D, Cummings J, Dwyer J, Iwatsubo T, Kosco-Vilbois M, McDade E, Mohs R, Scheltens P, Sperling R, Selkoe D.

Alzheimers Dement. 2025 Jan;21(1):e14342. doi: 10.1002/alz.14342. Epub 2024 Nov 13.

Mass spectrometry-based methods for biofluid biomarkers for progressive diseases: amyloid peptides and dystrophins

Niwa M, Noda K, Kobayashi Y, Kageyama I, Kodama K.

Bioanalysis. 2025 May;17(10):671-680. doi: 10.1080/17576180.2025.2515011. Epub 2025 Jun 4.

Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease

Cline EN, Antwi-Berko D, Sundell K, Johnson E, Hyland M, Zhang H, Vanderstichele H, Kaplow J, Dean RA, Stoops E, Vanmechelen E, Koel-Simmelink MJA, Teunissen CE, Sethuraman G, Feaster T, Siemers E, Jerecic J.

J Prev Alzheimers Dis. 2025 Apr;12(4):100082. doi: 10.1016/j.tjpad.2025.100082. Epub 2025 Feb 17.

PDE5 Inhibitors as Modulators of Alzheimer's-Associated Inflammation and Oxidative Stress: A Meta-Analytical Assessment of Preclinical Studies

Uppuluri CT, Prasad YSKV, Asadi K, Kumari TP, Pelluri R, Chakravarthi G, Nalluri BN, Gurram PC.

Mol Neurobiol. 2025 Dec 23;63(1):322. doi: 10.1007/s12035-025-05635-5.

Exploring precision medicine by utilizing individual genetic information for the management of Alzheimer's disease

Kanda A, Rani A, Mazumder A.

Pharmacogenomics. 2025 Jul-Aug;26(10-12):455-474. doi: 10.1080/14622416.2025.2560296. Epub 2025 Sep 15.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias